Current State of the Development of Therapies for Emergency Prophylaxis and Treatment of Ebola Virus Disease

• Published in: Problemy osobo opasnyh infekcij no. 3; pp. 98 - 103
• Main Authors: Petrov, A. A., Lebedev, V. N., Plekhanova, T. M., Stovba, L. F., Borisevich, G. V., Sidorova, O. N., Chukhralya, O. V., Borisevich, S. V.
• Format: Journal Article
• Language: English; Russian
• Published: Federal Government Health Institution, Russian Research Anti-Plague Institute “Microbe” 20.09.2015
• Subjects: anti-sense phosphordiamidate morpholine oligomers; ebola virus; emergency prophylaxis and treatment; hemorrhagic fever; medical products; monoclonal antibodies; small interfering rna; virus-specific antibodies; антисмысловые фосфордиамидатные морфолиновые олигомеры; вирус эбола; вирусспецифические антитела; лекарственные средства; малые интерферирующие рнк; моноклональные антитела; экстренная профилактика и лечение
• DOI: 10.21055/0370-1069-2015-3-98-103
• ISSN: 0370-1069

Nowadays vaccination of the population living in the endemic regions and widespread implementation of the potent therapies for the emergency prophylaxis and treatment into the clinical practice are regarded as the basic efficient and cost-effective measures for Ebola epidemic spread control. Objective of the review is to analyze current state of the development of aids for the immediate prophylaxis and treatment of Ebola fever. Focus area of the activities is the construction of drugs on the basis of virus-specific anti-bodies (including monoclonal), small interfering RNA, and anti-sense phosphordiamidate morpholine oligomers and interferons. The paper discusses the most significant achievements in this sphere.